Patents by Inventor Harald WEINSTABL

Harald WEINSTABL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240109913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 4, 2024
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Publication number: 20220144810
    Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 25, 2020
    Publication date: May 12, 2022
    Inventors: Andreas MANTOULIDIS, Andreas GOLLNER, Dirk KESSLER, Laetitia Janine MARTIN, Harald WEINSTABL
  • Patent number: 11304929
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 19, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Georg Dahmann, Matthias Treu, Bernd Wellenzohn, Stephan Karl Zahn
  • Publication number: 20220008386
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: March 18, 2018
    Publication date: January 13, 2022
    Inventors: Harald WEINSTABL, Georg DAHMANN, Matthias TREU, Bernd WELLENZOHN, Stephan Karl ZAHN
  • Publication number: 20210101912
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Patent number: 10919913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10882866
    Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Patent number: 10717742
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Patent number: 10576064
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Andreas Gollner, Juergen Ramharter, Tobias Wunberg
  • Publication number: 20190169209
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Patent number: 10246467
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: April 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Patent number: 10138251
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Tobias Wunberg
  • Publication number: 20180291030
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG
  • Publication number: 20180273541
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 27, 2018
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • Publication number: 20170247394
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 31, 2017
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Publication number: 20170174695
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: October 7, 2016
    Publication date: June 22, 2017
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • Publication number: 20160052938
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: August 20, 2015
    Publication date: February 25, 2016
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Publication number: 20160000764
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Harald WEINSTABL, Andreas GOLLNER, Juergen RAMHARTER, Tobias WUNBERG
  • Publication number: 20150291611
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: April 10, 2015
    Publication date: October 15, 2015
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG